Pacific Biosciences of California, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $160.0M | $154.0M | $200.5M | $128.3M | $130.5M | $78.9M | $90.9M |
| Cost of Revenue | — | $114.2M | $116.7M | $147.7M | $79.3M | $71.7M | $46.3M | $56.3M |
| Gross Profit | — | $45.8M | $37.3M | $52.8M | $49.0M | $58.9M | $32.6M | $34.6M |
| Gross Margin | — | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% | 38.0% |
| Operating Expenses | ||||||||
| Research & Development | — | $97.3M | $134.9M | $187.2M | $193.0M | $112.9M | $64.2M | $59.6M |
| SG&A Expense | — | $141.5M | $175.0M | $169.8M | $160.9M | $124.1M | $72.8M | $75.5M |
| Operating Income | — | $-553.9M | $-474.3M | $-334.5M | $-307.2M | $-210.4M | $-104.4M | $-100.5M |
| Operating Margin | — | -346.2% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% |
| Interest Expense | — | — | — | $14.3M | $14.7M | $12.5M | $267.0K | $2.6M |
| Pretax Income | — | $-546.1M | $-309.5M | $-318.2M | $-314.2M | $-274.9M | $29.4M | $-84.1M |
| Income Tax Expense | — | $318.0K | $316.0K | $-11.4M | $0 | $-93.6M | — | — |
| Net Income | — | $-546.4M | $-309.9M | $-306.7M | $-314.2M | $-181.2M | $29.4M | $-84.1M |
| Net Margin | — | -341.5% | -201.2% | -153.0% | -244.9% | -138.9% | 37.3% | -92.6% |
| EPS (Basic) | — | $-1.82 | $-1.13 | $-1.21 | $-1.40 | $-0.89 | $0.18 | $-0.55 |
| EPS (Diluted) | — | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 |
| Shares Outstanding (Basic) | 302.0M | 300.0M | 274.5M | 253.6M | 224.6M | 204.1M | 165.2M | 152.5M |
| Shares Outstanding (Diluted) | 302.0M | 300.0M | 288.4M | 253.6M | 224.6M | 204.1M | 175.0M | 152.5M |
| Dividends Per Share | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |